ArticleFrontiers in microbiology2016
Identification of Candida haemulonii Complex Species: Use of ClinProTools(TM) to Overcome Limitations of the Bruker Biotyper(TM), VITEK MS(TM) IVD, and VITEK MS(TM) RUO Databases.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.MicrobiologyOpen · 2018Pooled it
- Silent Outbreaks ofAntibiotics (Basel, Switzerland) · 2026Article
- Fatty Acid Profiling Identification Method of Emerging Fungal PathogenJournal of fungi (Basel, Switzerland) · 2026Article
- A dual-phase strategy to integrate the VITEK MS RUO database into routine clinical practice: from validation of analytical performance to implementation of an automated workflow.Frontiers in cellular and infection microbiology · 2026Article
- Molecular Detection ofJournal of fungi (Basel, Switzerland) · 2023Article
- Candida haemulonii complex, an emerging threat from tropical regions?PLoS neglected tropical diseases · 2023Review
- Whole-genome sequencing of Candida haemulonii species complex from Brazil and the United States: Genetic diversity and antifungal susceptibility.Medical mycology · 2023Article
- First two fungemia cases caused byFrontiers in microbiology · 2022Article
- Identification of Bacteria Associated with Post-Operative Wounds of Patients with the Use of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Approach.Molecules (Basel, Switzerland) · 2021Article
- Review
- Review
- Mass Spectrometry: A Rosetta Stone to Learn How Fungi Interact and Talk.Life (Basel, Switzerland) · 2020Review
- First Genome Sequences of Two Multidrug-ResistantFrontiers in microbiology · 2020Article
- Article
- Hospital Laboratory Survey for Identification ofJournal of fungi (Basel, Switzerland) · 2019Article
- Evaluation of Vitek MS for Differentiation ofJournal of clinical microbiology · 2019Article
- Candida auris: an Emerging Fungal Pathogen.Journal of clinical microbiology · 2018Review
- Candida auris: a Review of the Literature.Clinical microbiology reviews · 2018Review
- Oligonucleotide Array and VITEK Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Species Identification of Blood Yeast Isolates.Frontiers in microbiology · 2018Article
- Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry in Clinical Microbiology: What Are the Current Issues?Annals of laboratory medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida haemulonii is now considered a complex of two species and one variety: C. haemulonii sensu stricto, Candida duobushaemulonii and the variety C. haemulonii var. vulnera. Identification (ID) of these species is relevant for epidemiological purposes and for therapeutic management, but the different phenotypic commercial systems are unable to provide correct species ID for these emergent pathogens. Hence, we evaluated the MALDI-TOF MS performance for the ID of C. haemulonii species, analyzing isolates/strains of C. haemulonii complex species, Candida pseudohaemulonii and Candida auris by two commercial platforms, their databases and softwares. To differentiate C. haemulonii sensu sctricto from the variety vulnera, we used the ClinProTools(TM) models and a single-peak analysis with the software FlexAnalysis(TM). The Biotyper(TM) database gave 100% correct species ID for C. haemulonii sensu stricto, C. pseudohaemulonii and C. auris, with 69% of correct species ID for C. duobushaemulonii. Vitek MS(TM) IVD database gave 100% correct species ID for C. haemulonii sensu stricto, misidentifying all C. duobushaemulonii and C. pseudohaemulonii as C. haemulonii, being unable to identify C. auris. The Vitek MS(TM) RUO database needed to be upgraded with in-house SuperSpectra to discriminate C. haemulonii sensu stricto, C. duobushaemulonii, C. pseudohaemulonii, and C. auris strains/isolates. The generic algorithm model from ClinProTools(TM) software showed recognition capability of 100% and cross validation of 98.02% for the discrimination of C. haemulonii sensu stricto from the variety vulnera. Single-peak analysis showed that the peaks 5670, 6878, or 13750 m/z can distinguish C. haemulonii sensu stricto from the variety vulnera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.